In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Contemporary Treatment of Intracranial Dural Arteriovenous Fistulas (DAVFS): Toward Zero Mortality and Morbidity?

    Final Number:
    239

    Authors:
    Giuseppe Lanzino MD; Ondra Petr MD; David J. Daniels MD, PhD; Michael J. Link MD

    Study Design:
    Clinical trial

    Subject Category:
    Vascular Malformations

    Meeting: AANS/CNS Cerebrovascular Section 2016 Annual Meeting

    Introduction: Different treatment modalities (endovascular embolization, stereotactic radiosurgery, surgery, and medical treatment) can be utilized alone or in combination to treat intracranial DAVFs. An “individualized” approach, tailored to the clinical characteristics of each patient may lead to effective treatment of DAVFs with very low morbidity.

    Methods: We performed a retrospective analysis of prospective collected data on 103 consecutive patients (52 males and 51 females, mean age 61.7 years) with 108 intracranial DAVFs evaluated and/or treated by the senior author (GL) at the Mayo Clinic in Rochester, MN between January 2008 and April 2015.

    Results: The more common DAVFs locations were the transverse/sigmoid sinus (38.9%), tentorial (27.8%) and the cavernous sinus region (14.8%). According to the Cognard classification, Type I (24.1%), Type III (23.1%) and Type II a (14.8%) were the most common types. Twelve percent of patients presented with hemorrhage. Thirteen patients were managed conservatively and of those undergoing invasive treatment, 63.3% underwent a single therapeutic modality and 36.7% were treated with multimodality therapy. There was no mortality and no major permanent neurological morbidity. Mild periprocedural neurological complications (self-assessed mRS 0-1) occurred in 3 patients (3.3%). One patient was lost to follow-up. After a mean follow-up of 44.3 months, there were no hemorrhages related to the DAVF and every patient experienced improvement or at least stabilization of symptoms.

    Conclusions: With judicious utilization of various therapeutic modalities available, intracranial DAVFs can be successfully treated with very low morbidity.

    Patient Care: Our study shows the contemporary complex treatment management of patients with intracranial DAVFs with negligible complications and high rates of long-term good neurological outcome.

    Learning Objectives: Contemporary treatment options and their appropriate utilization allow the optimal complex management of patients with intracranial DAVFs with negligible treatment complication rates. It is crucial to assess the risk-benefit ratio of all available treatment modalities compared with possible risks of conservative management. We strongly suggest that the decision-making process should be individualized based on lesion's angiographic architecture and risks of treatment.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy